BRAFV600E Mutation Analysis of Thyroid Nodules Needle Aspirates in Relation to Their Ultrasongraphic Classification: A Potential Guide for Selection of Samples for Molecular Analysis

Nam, Sang Yu; Han, Boo‐Kyung; Ko, Eun Young; Kang, Seok Seon; Hahn, Soo Yeon; Hwang, Ji-Young; Nam, Myung Hyun; Kim, Jong-Won; Chung, Jae Hoon; Oh, Young Lyun; Shin, Jung Hee

doi:10.1089/thy.2009.0226

Cited by 69 publications

(49 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is comparable to numbers between 15 and 39% that have been reported by other authors in the literature [16,17]. Sixteen of these 19 nodules had histologic follow-up and they all had a diagnosis of PTC.…”

Section: Discussionsupporting

confidence: 87%

BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance

et al. 2011

View full text Add to dashboard Cite

Background/Objective: The Bethesda 2007 Thyroid Cytology Classification defines atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) as a heterogeneous category of cases that are neither convincingly benign nor sufficiently atypical for a diagnosis of follicular neoplasm or suspicious for malignancy. At our institution, we refer to these cases as ‘indeterminate’ and they are further subclassified into two categories. BRAF mutation occurs in 40–60% of papillary thyroid carcinoma (PTC). In this study, we examined cases in the AUS/FLUS category in correlation with BRAF mutation analysis and surgical pathology outcome. Study Design: Thyroid fine-needle aspiration (FNA) cytology specimens interpreted as ‘indeterminate’ were selected from our files, and available remnants of thin-layer processed specimens were used for BRAF mutation analysis. Surgical pathology reports were reviewed for the final outcomes in these patients. Results: Of the 84 indeterminate cases with BRAF mutation analysis, only 49 had follow-up with surgical intervention. Sixteen cases had BRAF mutation. All of the BRAF-positive cases had a final diagnosis of PTC. Conclusions: The sensitivity and specificity of BRAF mutation in detecting PTC in FNA specimens with indeterminate diagnosis was 59.3 and 100%, respectively, while the positive and negative predictive values were 100 and 65.6%, respectively. The limited data supports the use of BRAF mutation analysis to predict the risk of malignancy in patients with indeterminate thyroid FNAs.

show abstract

Section: Discussionsupporting

confidence: 87%

BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance

et al. 2011

View full text Add to dashboard Cite

show abstract

“…According to the scientific resource reviews outlined in Table 3, the vast majority of studies were performed with a large number of samples, with several authors finding no sensitive phenotype of strains with mutations in codon 306 (15,16). These results are quite compatible with the results of this research.…”

Section: Discussionsupporting

confidence: 83%

Performance Assessment of The Polymerase Chain Reaction-restriction Fragment Length Polymorphism Method for Rapid Detection of Susceptibility to Ethambutol and Molecular Prediction of XDR Tuberculosis in Clinical Isolates of Mycobacterium Tuberculosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A recent study showed BRAF mutation was detected in 67% of ‘ultrasound-positive’ thyroid nodules as opposed to 14% of ‘ultrasound negative’ lesions [13]. The value of performing BRAF mutational analysis assumes a more important role when done in a BRAF V600E -prevalent population, where it has been clearly shown to increase the diagnostic accuracy of FNA [14].…”

Section: Future Trendsmentioning

confidence: 99%

Thyroid Cytopathology: Bethesda and Beyond

2010

View full text Add to dashboard Cite

Thyroid nodules are commonly encountered in clinical practice. Although the overwhelming majority of them turn out to be benign, the small subset of cancerous nodules needs to be accurately identified for optimal and timely surgical management. Fine-needle aspiration has proven to be the most valuable diagnostic modality for pre-operative distinction of benign from malignant nodules. The recently introduced and much anticipated Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has standardized our diagnostic approach to reporting and cytomorphological criteria. TBSRTC has well-defined and rational management algorithms with implicit risk of malignancy in each of the 6 diagnostic categories. Recently published data supports the clinical utility and wide acceptance of TBSRTC by both practicing pathologists and clinicians. The problematic category of ‘indeterminate’ cytopathologic diagnoses has led to the discovery and development of unique and useful molecular markers, such as BRAF, which have displayed promising potential in recently published studies. As a result of the publication of TBSRTC, in 2009 the American Thyroid Association revised its clinical guidelines for the management of patients with thyroid disease and TBSRTC offers a useful source of information for the pathologist as well.

show abstract

BRAF^V600E Mutation Analysis of Thyroid Nodules Needle Aspirates in Relation to Their Ultrasongraphic Classification: A Potential Guide for Selection of Samples for Molecular Analysis

Cited by 69 publications

References 22 publications

<i>BRAF</i> Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance

<i>BRAF</i> Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance

Performance Assessment of The Polymerase Chain Reaction-restriction Fragment Length Polymorphism Method for Rapid Detection of Susceptibility to Ethambutol and Molecular Prediction of XDR Tuberculosis in Clinical Isolates of Mycobacterium Tuberculosis

Thyroid Cytopathology: Bethesda and Beyond

Contact Info

Product

Resources

About